



## **Neurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference**

December 7, 2016

**Live Audio Webcast will be on December 14, 2016**

SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference in New York City.

The live presentation takes place on Wednesday, December 14 at 8:00am ET (5:00am PT). The presentation will be webcast and may be accessed on the Company's website at <http://www.neurocrine.com>.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

### **About Neurocrine Biosciences**

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and INGREZZA (valbenazine or NBI-98854), a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine plans to commercialize INGREZZA in the United States upon approval by the FDA.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-2016-bmo-capital-markets-prescription-for-success-healthcare-conference-300372381.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, (858) 617-7600